Boston Scientific upgraded to Buy from Hold at Deutsche Bank

Deutsche Bank upgraded Boston Scientific (BSX) to Buy from Hold with a price target of $108, up from $87. Boston Scientific’s :story has become simpler” following Johnson & Johnson’s (JNJ) Varipulse getting pulled from the shelves, the analyst tells investors in a research note. The firm says that as one of the “best-in-class medtech names,” Boston Scientific is poised again to outperform in 2025. For both short-term and long-term investors, the recent news about Varipulse “removes the major overhang” in 2025 and can allow Boston Scientific to continue to “grind higher throughout the year,” contends Deutsche Bank.